Citations

Clear

6273 citation(s) found for "To, Andrew".

Efficacy and Safety of a Nicotine Mouth Spray for Smoking Cessation: A Randomized, Multicenter, Controlled Study in a Naturalistic Setting
Nides, Mitchell, Danielsson, Tobias , Saunders, Frederick, Perfekt, Roland, Kapikian, Roxanne, Solla, Janice, Leischow, Scott J. , Myers, Andrew , Saunders, Frederick

Mayo Clinic

Nicotine & Tobacco Research | November 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ntr/nty246 | PMID 30452732 Get It

Approach to Using Trend Arrows in the FreeStyle Libre Flash Glucose Monitoring Systems in Adults
Kudva, Yogish C. , Ahmann, Andrew , Bergenstal, Richard M. , Gavin, James R. , Kruger, Davida , Midyett, L. Kurt , Miller, Eden , Harris, Dennis R. , Ahmann, Andrew J , Kruger, Davida F

Mayo Clinic

Journal of the Endocrine Society | November 14, 2018 | Volume: 2 | Issue: 12 | Pages: 1320-1337

10.1210/js.2018-00294 | PMID 30474069 Get It

Models of Peer Support to Remediate Post-Intensive Care Syndrome: A Report Developed by the Society of Critical Care Medicine Thrive International Peer Support Collaborative*
McPeake, Joanne , Hirshberg, Eliotte L. , Christie, LeeAnn M., Drumright, Kelly, Hough, Catherine L. , Meyer, Joel , Wade, Dorothy , Andrews, Adair, Bakhru, Rita N. , Bates, Samantha , Barwise, John, Beesley, Sarah J. , Boehm, Leanne M. , Brown, Sheryl, Clay, Alison S. , Firshman, Penelope , Greenberg, Steven B. , Harris, Wendy, Hope, Aluko A. , Hopkins, Ramona O., Howell, David C., Jackson, James C. , Johnson, Annie, Kross, Erin K. , Lamas, Daniela, MacLeod-Smith, Belinda, Mandel, Ruth, Marshall, John C., Nackino, Megan, Quasim, Tara , Sevin, Carla M. , Slack, Andrew, Spurr, Rachel, Still, Mary, Thompson, Carol, Weinhouse, Gerald L., Wilcox, M. Elizabeth , Iwashyna, Theodore J. , Haines, Kimberley , Bastarache, Julie A. , Hill, Christopher, Hodgson, Carol Lynette , Holdsworth, Clare, Howell, David C. J., Janssen, Anna, Mikkelsen, Mark E.

Mayo Clinic

Critical Care Medicine | November 13, 2018 | Volume: 47 | Issue: 1 | Pages: e21-e27

10.1097/ccm.0000000000003497 | PMID 30422863 Get It

Objectives: Patients and caregivers can experience a range of physical, psychologic, and cognitive problems following critical care discharge. The use of peer support has been proposed as an innovative support mechanism. Design: We sought to identify technical, safety, and procedural aspects of existing operational models of peer support, among the Society of Critical Care Medicine Thrive Peer Support Collaborative. We also sought to categorize key distinctions between these models and elucidate barriers and facilitators to implementation. Subjects and Setting: Seventeen Thrive sites from the United States, United Kingdom, and Australia were represented by a range of healthcare professionals. Measurements and Main Results: Via an iterative process of in-person and email/conference calls, members of the Collaborative defined the key areas on which peer support models could be defined and compared, collected detailed self-reports from all sites, reviewed the information, and identified clusters of models. Barriers and challenges to implementation of peer support models were also documented. Within the Thrive Collaborative, six general models of peer support were identified: community based, psychologist-led outpatient, models-based within ICU follow-up clinics, online, groups based within ICU, and peer mentor models. The most common barriers to implementation were recruitment to groups, personnel input and training, sustainability and funding, risk management, and measuring success. Conclusions: A number of different models of peer support are currently being developed to help patients and families recover and grow in the postcritical care setting.
Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS ® ) Society Recommendations: 2018
Gustafsson, Ulf , Scott, Michael J. , Hübner, Martin , Demartines, Nicolas , Rockall, Timothy , Young‐Fadok, Tonia M., Soop, Mattias , Boer, Hans D. de , Chang, George J. , Keßler, Hermann, Whang, Edward E. , Fawcett, William , Carli, F. , Lobo, Dileep N. , Rollins, Katie E. , Balfour, Angie , Ljungqvist, Olle , Demartines, N , Lobo, D N , Hübner, Martin , Nygren, Jonas , Francis, Nader Kamal , Hill, Andrew Graham , Urman, Richard D , Fichera, A., Grass, Fabian , Baldini, G., Riedel, Bernhard

Mayo Clinic

World Journal of Surgery | November 13, 2018 | Volume: 43 | Issue: 3 | Pages: 659-695

10.1007/s00268-018-4844-y | PMID 30426190 Get It

Abstract Background This is the fourth updated Enhanced Recovery After Surgery (ERAS ® ) Society guideline presenting a consensus for optimal perioperative care in colorectal surgery and providing graded recommendations for each ERAS item within the ERAS ® protocol. Methods A wide database search on English literature publications was performed. Studies on each item within the protocol were selected with particular attention paid to meta‐analyses, randomised controlled trials and large prospective cohorts and examined, reviewed and graded according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Results All recommendations on ERAS ® protocol items are based on best available evidence; good‐quality trials; meta‐analyses of good‐quality trials; or large cohort studies. The level of evidence for the use of each item is presented accordingly. Conclusions The evidence base and recommendation for items within the multimodal perioperative care pathway are presented by the ERAS ® Society in this comprehensive consensus review.
Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review
Lawton, Andrew J. , Lee, Kathleen A., Ferrone, Marco , Rades, Dirk , Abrahm, Janet L. , Cheville, Andrea , Balboni, Tracy Anne

Mayo Clinic

Journal of Clinical Oncology | November 5, 2018 | Volume: 37 | Issue: 1 | Pages: 61-71

10.1200/jco.2018.78.1211 | PMID 30395488 Get It

PurposeMetastatic spinal cord compression (MSCC) can be a catastrophic manifestation of advanced cancer that causes immobilizing pain and significant neurologic impairment. Oncologists can protect their patients by having a high index of suspicion for MSCC when patients present with new or worsening back pain before motor, sensory, bowel, or bladder deficits develop. We provide an updated, evidence-based narrative review of the presentation, diagnosis, and treatment of MSCC.MethodsThis narrative review was conducted by searching MEDLINE and Cochrane Database of Systematic Reviews for relevant literature on the presentation, diagnosis, and treatment of patients with MSCC. The article addresses the key elements of MSCC management germane to the medical oncologist, with special attention given to pain and symptom management, decision making with regard to surgery and radiation therapy, the importance of rehabilitative care, and the value of a multidisciplinary approach.ResultsMagnetic resonance imaging of the entire spine is recommended for the diagnosis of MSCC. Treatment includes glucocorticoid therapy, pain management, radiation therapy with or without surgery, and specialized rehabilitation. When formulating a treatment plan, clinicians should consider the patient’s care goals and psychosocial needs.ConclusionPrompt diagnosis and treatment of MSCC can reduce pain and prevent irreversible functional loss. Regular collaboration among multidisciplinary providers may streamline care and enhance achievement of treatment goals.
Obese Patients Benefit, but do not Fare as Well as Nonobese Patients, Following Lumbar Spondylolisthesis Surgery: An Analysis of the Quality Outcomes Database
Chan, Andrew K. , Bisson, Erica F. , Bydon, Mohamad , Glassman, Steven D. , Foley, Kevin T. , Potts, Eric A. , Shaffrey, Christopher I. , Shaffrey, Mark E., Coric, Domagoj , Knightly, John J. , Park, Paul , Wang, Michael Y. , Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L. , Virk, Michael S, Kerezoudis, Panagiotis, DiGiorgio, Anthony M. , Haid, Regis W., Mummaneni, Praveen V. , Virk, Michael S, Kerezoudis, Panagiotis

Mayo Clinic

Neurosurgery | November 5, 2018 | Volume: 86 | Issue: 1 | Pages: 80-87

10.1093/neuros/nyy589 | PMID 30541141 Get It

Abstract BACKGROUND Given recent differing findings following 2 randomized clinical trials on degenerative lumbar spondylolisthesis (DLS) surgery, there is a need to better define how subsets of patients fare following surgery. OBJECTIVE To investigate the impact of obesity on patient-reported outcomes (PROs) following DLS surgery. METHODS A total of 12 high-enrolling sites were queried, and we found 797 patients undergoing surgery for grade 1 DLS. For univariate comparisons, patients were stratified by BMI ≥ 30 kg/m 2 (obese) and < 30 kg/m 2 (nonobese). Baseline, 3-mo, and 12-mo follow-up parameters were collected. PROs included the North American Spine Society satisfaction questionnaire, numeric rating scale (NRS) back pain, NRS leg pain, Oswestry Disability Index (ODI), and EuroQoL-5D (EQ-5D) Questionnaire. RESULTS We identified 382 obese (47.9%) and 415 nonobese patients (52.1%). At baseline, obese patients had worse NRS back pain, NRS leg pain, ODI, and EQ-5D scores ( P < .001, P = .01, P < .001, and P = .02, respectively). Both cohorts improved significantly for back and leg pain, ODI, and EQ-5D at 12 mo ( P < .001). At 12 mo, similar proportions of obese and nonobese patients responded that surgery met their expectations (62.6% vs 67.4%, P = .24). In multivariate analyses, BMI was independently associated with worse NRS leg pain and EQ-5D at 12 mo ( P = .01 and P < .01, respectively) despite adjusting for baseline differences. CONCLUSION Obesity is associated with inferior leg pain and quality of life—but similar back pain, disability, and satisfaction—12 mo postoperatively. However, obese patients achieve significant improvements in all PRO metrics at 12 mo.
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Chhabra, Saurabh , Ahn, Kwang Woo , Hu, Zhen‐Huan , Jain, Sandeep , Černý, Jan , Copelan, Edward A. , Daly, Andrew , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hamilton, Betty K. , Hildebrandt, Gerhard , Hsu, Jack W., Inamoto, Yoshihiro , Kanate, Abraham S. , Khoury, H. Jean, Litzow, Mark R. , Nathan, Sunita , Olsson, Richard F. , Pawarode, Attaphol , Ringdén, Olle , Rowe, Jacob M. , Saad, Ayman , Schouten, Harry C. , Seo, Sachiko , Shah, Nirav N. , Solh, Melhem , Üstün, Celalettin , Woolfrey, Ann E. , Alyea, Edwin P. , Kalaycio, Matt, Sobecks, Ronald , Saber, Wael , Cerny, Jan , Gadalla, Shahinaz M , Nathan, Sunita , Saad, Ayman , Olsson, Richard F , Ringden, Olov , Chhabra, Saurabh , Assal, Amer , Gale, Robert Peter , Lazarus, Hillard M. , Savani, Bipin N. , Stuart, Robert K. , Yared, Jean A. , Popat, Uday R

Mayo Clinic

Blood Advances | November 5, 2018 | Volume: 2 | Issue: 21 | Pages: 2922-2936

10.1182/bloodadvances.2018024844 | PMID 30396912 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.